Immature teratoma arising from uterine corpus in an 11-year-old girl: Case report and review of the literature

Yinling Zhao*, Tianhui Xu*, Xinhua Bu, Donglan Yuan, Yiqun Wu and Hua Qian

Department of Obstetrics and Gynaecology, Hospital Affiliated 5 to Nantong University (Taizhou People’s Hospital), Taizhou, China

Abstract

Teratomas are one of the most common germ cell tumors, and they usually occur in ovaries. Extragonadal teratomas are rare, especially immature ones. Only several cases of primary teratomas of the uterus have been reported since 1929. Here, the case of an 11-year-old patient who had a 6-month history of sustained abnormal vaginal discharge is presented. Transabdominal ultrasonography revealed a solid mass in her uterus, resulting in the patient undergoing surgery. Examination of PET-CT scans revealed a mass in the right ovary of the patient 20 days after surgery. The patient underwent a second surgery followed by chemotherapy. This is the youngest case among reported patients of primary immature uterine teratoma, and this patient showed no evidence of recurrence during 2 years of follow-up.

Key words: immature teratoma, mature teratoma, uterine teratoma.

Introduction

Teratomas are one of the most common germ cell tumors classifiable as mature or immature.1 The tumor characteristics and the extent of malignancy depend on the differentiation degree. An immature teratoma is a malignant tumor, which accounts for 1–3% of ovarian teratomas.2 Teratomas usually arise in the gonads, while extragonadal teratomas are very rare and account for 2–5% of germ cell tumors.3 Primary teratomas of the uterus have rarely been reported since 1929.4–7 Here, the case of an 11-year-old patient who had an immature teratoma in her uterus and a mature teratoma in her ovary is presented.

Case Report

An 11-year-old girl with no special medical history went to the hospital in February 2018 with a 6-month history of sustained abnormal vaginal discharge. A mass could be seen in the orifice of her vagina through a gynecologic examination. Transabdominal ultrasonography revealed a solid mass measuring 11 × 6.5 cm from the uterus to the vagina with heterogeneous internal echo (Figure 1A). Tumor markers, including AFP, CA125 and CA19-9, were all within normal limits. The first menstrual period of the patient was in July 2017. The menstrual cycle was not regular with about 30–50 days. The last menstruation was on December 20, 2017. The fertility of the patient was chosen to be retained, considering that she is an 11-year-old girl. The mass was moved by a hystero-scopic transcervical resection in February 2018. During surgery, a 12 × 6 cm mass was found protruding from the posterior uterine wall into the vagina through the cervical canal. The characteristics of the mass were yellow and soft. Most of the mass was then cut out by an experienced gynecologist. Microscopically, the mass was revealed to be an immature teratoma composed of mature and immature...
embryonic layers, especially including immature neuroepithelial elements. Subsequent Immunohistochemistry showed positive staining of Syn+, Nestin+, CD99+, Fli-1+, SAL4+, P53+, AEI/AE3− and Desmin − (Figure 1B).

Examination of ultrasound and CT scans showed no residual teratoma after the operation, but a mass was present in the right ovary of the patient 20 days after surgery. It measured about 3.1 × 3.2 cm in size, with fat density and dot-strip calcification, suggesting that it may be a teratoma. The mass was not noticed before. Inevitably, the patient underwent a second operation via a laparoscope in March 2018. During the operation, a 3.1 × 3.2 cm mass was removed from the right ovary. Microscopically, the mass was revealed to be mature teratoma (Figure 1C). The following treatment strategy included six courses of chemotherapy (BEP regimen) based on bleomycin (15 mg/body, days 1–2), etoposide (100 mg/m², days 1–2) and cisplatin (30 mg/m², days 1–2) every

Figure 1 A (a) Ultrasonography showing a solid mass measuring 11 × 6.5 cm from uterus to vagina with heterogenous internal echo; (b) ultrasound image after lesion excision; (c) ultrasonography showing a solid mass of the right ovary measuring 3.1 × 3.2 cm. B (a) Histopathological appearances of malignant uterine teratoma; (b) immunohistochemical analysis showing positive staining for Syn. C Histopathological appearances of mature ovarian teratoma.
The patient was well after 2 years of follow-up post-surgery. No residual tumors were found through regular examinations of ultrasound and CT scans. As well, the patient no longer has any abnormal symptoms.

Discussion

Extragonadal germ cell tumors can arise anywhere along germ cell migration routes. Teratomas are the most common germ cell tumors, and the occurrence of primary uterine teratomas is rare. The first uterine teratoma case was reported in 1929, with only a few cases being reported after that. Primary immature uterine teratoma was particularly rare, with only eight cases reported according to statistics investigated for this paper (Table 1). However, this case is the first case where the patient was only 11 years old, who was also the youngest case among all reported patients of primary immature uterine teratoma.

Two main theories about uterine teratoma origins can be discussed. The first theory suggests that they arise from primordial fetal germ cells when migrating abnormally from the fetal yolk sac endoderm to the gonadal ridge during early embryogenesis. These tumors are considered to arise in middle structures like the uterus. Another theory proposes that they arise from residual fetal tissue implemented during missed abortion or fertility processes. The patient in the case of this paper is an 11-year-old girl with neither a history of abortion nor instrumentation. Therefore, the second theory was ruled out in this case.

In uterine teratoma reports, patient ages ranged from 15 to 90. In this case, the age of the patient, 11-year-old, was the youngest in all reports since 1992. Usually, no special symptoms occur with uterine teratoma, including vaginal bleeding, lower abdominal pain, pelvic inflammation and other single

| Symptoms                        | Age  | Site of tumor | Histology                        | Treatment                                      | Follow-up                  | Author                      |
|---------------------------------|------|---------------|----------------------------------|-----------------------------------------------|----------------------------|-----------------------------|
| Vaginal bleeding                | 37   | Not specified | Immature teratoma, grade 2+      | TAH+radiotherapy                              | No recurrence              | Ansa-Boateng et al. (1985)  |
| Pelvic pain, lower abdominal     | 36   | fundus        | Immature teratoma, grade 3       | TAH+chemotherapy (VAC*2)                       | No recurrence after 5 years| Iwanaga et al. (1993)       |
| distention                      |      |               |                                  |                                               |                            |                             |
| Vaginal bleeding                 | 15   | Not specified | Immature teratoma, high grade    | Lesion excision + chemotherapy                | Not specified              | Gomez-Lobo et al. (2007)    |
| Pelvic pain                     |      |               |                                  |                                               |                            |                             |
| Vaginal bleeding                 | 82   | Corpus        | Immature teratoma                | TAH-BSO                                       | Relapse after 6 months     | Newsom-Davis et al. (2009)  |
| Urinary symptoms, lower         | 56   | Corpus        | Immature teratoma                | TAH                                           | Relapse After 3 months     | Ben-Ameur et al. (2013)     |
| abdominal distention            |      |               |                                  |                                               |                            |                             |
| Vaginal bleeding, malodorous     | 23   | Corpus and cervix | Immature teratoma, grade 2+     | TAH + BSO + lymph node Dissection + BEP*3     | Disease-free after 12 months| Teixeira Souza et al. (2014)|
| discharge                       |      |               | carcinoid elements                |                                               |                            |                             |
| menometrorrhagia and            | 29   | cervix        | Immature teratoma, grade 3       | TAH + BSO + lymph node Dissection + omentectomy| Disease-free after 36 months| Hana Saffar et al. (2016)   |
| intermenstrual bleeding         |      |               |                                  |                                               |                            |                             |
| Vaginal bleeding                 | 46   | endometrium   | Immature teratoma, grade 1       | Lesion excision                               | Disease-free after 5 months| Simona Stolnicu et al. (2017)|
| Abnormal vaginal discharge       | 11   | Corpus        | Immature teratoma                | Lesion excision + BEP                         | Disease-free after 2 years | Our case, 2018              |

BEP: bleomycin, etoposide, cisplatin; BSO: bilateral salpingooophorectomy; EP: etoposide, cisplatin; ET: etoposide, paclitaxel; IT: immature teratoma; ns: not specified; TAH: total abdominal hysterectomy; TP: palcitaxel, cisplatin; VAC: vincristine, actinomycin-D, and cyclophosphamide.
Case of immature teratomas

or combined symptoms\(^\text{10}\). In this case, the vaginal fluid was treated for 6 months. For the uterine teratoma diagnosis, auxiliary examination mainly includes ultrasound, CT scan or magnetic resonance imaging. Imaging manifestations are also varied without specificity, and the examination results will be affected by location, size and so on. Therefore, making an accurate diagnosis via auxiliary examination before the operation is difficult, and it also needs to be differentiated from other myomas\(^\text{11}\). The final pathology is the gold standard for disease diagnosis. In this case, the initial gynecological examination of the patient found a vaginal mass exfoliation, followed by ultrasonography. Before the operation, whether or not it was a uterine teratoma was unclear, but this was not determined until intraoperative and postoperative pathology revealed it to be an immature uterine teratoma. The main treatment of immature uterine teratoma is surgery, consisting of a complete tumor excision or radical hysterectomy with or without pelvic and para-aortic lymphadenectomy\(^\text{2,10}\). Considering the age of the patient, the operative method was chosen to preserve the fertility of the patient. Postoperative PET-CT scan reexamination revealed a mature teratoma of the right ovary, which had not been noticed before, and the reason for it was unknown. Therefore, a second operation was unavoidable.

No uniform consensus exists regarding chemotherapy and radiotherapy of uterine immature teratomas\(^\text{12}\). Among several reported cases, various therapeutic methods have been used; however, uterine teratoma prognosis is uncertain because of the small number of reported cases. The BEP regimen was chosen in this case, considering the operation mode and the postoperative state of the patient\(^\text{13}\). The patient showed no evidence of recurrence during 2 years of resulting follow-up. In conclusion, the therapeutic standard and prognosis of immature uterine teratoma remain unknown.

Acknowledgments

H. Q. was responsible for designing the study. Y. Z., T. X. and Y. W. were responsible for writing the protocol and report and collecting the data extraction. X. B. and D. Y. contributed to the statistical analysis and provided feedback on the report.

Disclosure

None declared.

References

1. Hording U, Rorth M. Germ cell tumors of the ovary. UFI 1985; 147: 784–788.
2. Lim SC, Kim YS, Lee YH, Lee MS, Lim JY. Mature teratoma of the uterine cervix with lymphoid hyperplasia. Pathol Int 2003; 53: 327–331.
3. Albany C, Einhorn LH. Extragonadal germ cell tumors: Clinical presentation and management. Curr Opin Oncol 2013; 25: 261–265.
4. Stolnicu S, Szekely E, Molnar C et al. Mature and immature solid teratomas involving uterine corpus, cervix, and ovary. Int J Gynecol Pathol 2017; 36: 222–227.
5. Souza KT, Negrao MV, da Silva Rocha LS et al. Immature uterine teratoma associated with uterine inversion. Rare Tumors 2014; 6: 5530.
6. Kamgobe E, Massinde A, Matovelo D, Ndaboine E, Rambau P, Chaula T. Uterine myometrial mature teratoma presenting as a uterine mass: A review of literature. BMC Clin Pathol 2016; 16: 5.
7. Saffar H, Nili F, Malek M, Jahanbin B, Ghahghaei Nezamabadi A. Primary immature teratoma of the uterus with peritoneal and lymph node involvement, case report. J Obstet Gynaecol 2017; 37: 1096–1098.
8. Newsom-Davis T, Poulter D, Gray R et al. Case report: Malignant teratoma of the uterine corpus. BMC Cancer 2009; 9: 195.
9. Tyagi SP, Saxena K, Rizvi R et al. Foetal remnants in the uterus and their relation to other uterine heterotopia. Histopathology 1979; 3: 339–345.
10. Ben Ameur El Youbi M, Mohtaram A, Kharmoum J et al. Primary immature teratoma of the uterus relapsing as malignant neuroepithelioma: Case report and review of the literature. Case Rep Oncol Med 2013; 2013: 971803.
11. Akai M, Isoda H, Sawada S et al. A case of struma uteri. AJR Am J Roentgenol 2005; 185: 216–218.
12. Vicus D, Beiner ME, Clarke B et al. Ovarian immature teratoma: Treatment and outcome in a single institutional cohort. Gyncol Oncol 2011; 123: 50–53.
13. Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology Group. J Clin Oncol 1994; 12: 701–706.